Virbac SA
PAR:VIRP
Profitability Summary
Virbac SA's profitability score is 56/100. We take all the information about a company's profitability (such as its margins, capital efficiency, free cash flow generating ability, and more) and consolidate it into one single number - the profitability score. The higher the profitability score, the more profitable the company is.
Score
We take all the information about a company's profitability (such as its margins, capital efficiency, free cash flow generating ability, and more) and consolidate it into one single number - the profitability score. The higher the profitability score, the more profitable the company is.
We take all the information about a company's profitability (such as its margins, capital efficiency, free cash flow generating ability, and more) and consolidate it into one single number - the profitability score. The higher the profitability score, the more profitable the company is.
Score
Score
Margins
Profit margins represent what percentage of sales has turned into profits. Simply put, the percentage figure indicates how many cents of profit the company has generated for each dollar of sale.
Profit margins help investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Earnings Waterfall
Virbac SA
|
Revenue
|
1.4B
EUR
|
|
Cost of Revenue
|
-459.8m
EUR
|
|
Gross Profit
|
937.6m
EUR
|
|
Operating Expenses
|
-708.6m
EUR
|
|
Operating Income
|
229m
EUR
|
|
Other Expenses
|
-83.7m
EUR
|
|
Net Income
|
145.3m
EUR
|
Margins Comparison
Virbac SA Competitors
| Country | Company | Market Cap |
Gross Margin |
Operating Margin |
Net Margin |
||
|---|---|---|---|---|---|---|---|
| FR |
|
Virbac SA
PAR:VIRP
|
2.8B EUR |
67%
|
16%
|
10%
|
|
| US |
|
Eli Lilly and Co
NYSE:LLY
|
635.2B USD |
83%
|
42%
|
26%
|
|
| UK |
|
Dechra Pharmaceuticals PLC
LSE:DPH
|
440.4B GBP |
56%
|
3%
|
-4%
|
|
| US |
|
Johnson & Johnson
NYSE:JNJ
|
419B USD |
68%
|
26%
|
25%
|
|
| CH |
|
Roche Holding AG
SIX:ROG
|
198.6B CHF |
74%
|
33%
|
14%
|
|
| UK |
|
AstraZeneca PLC
LSE:AZN
|
178.6B GBP |
82%
|
24%
|
15%
|
|
| CH |
|
Novartis AG
SIX:NOVN
|
190.2B CHF |
76%
|
33%
|
25%
|
|
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.4T DKK |
84%
|
46%
|
36%
|
|
| US |
|
Merck & Co Inc
NYSE:MRK
|
209.3B USD |
78%
|
38%
|
26%
|
|
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
183.4B USD |
68%
|
11%
|
-126%
|
|
| US |
|
Pfizer Inc
NYSE:PFE
|
141.9B USD |
74%
|
29%
|
17%
|
Return on Capital
Return on capital ratios give a sense of how well a company is using its capital (equity, assets, capital employed, etc.) to generate profits (operating income, net income, etc.). In simple words, these ratios show how much income is generated for each dollar of capital invested.
Return on Capital Comparison
Virbac SA Competitors
| Country | Company | Market Cap | ROE | ROA | ROCE | ROIC | ||
|---|---|---|---|---|---|---|---|---|
| FR |
|
Virbac SA
PAR:VIRP
|
2.8B EUR |
15%
|
9%
|
19%
|
12%
|
|
| US |
|
Eli Lilly and Co
NYSE:LLY
|
635.2B USD |
87%
|
16%
|
42%
|
23%
|
|
| UK |
|
Dechra Pharmaceuticals PLC
LSE:DPH
|
440.4B GBP |
-4%
|
-2%
|
2%
|
2%
|
|
| US |
|
Johnson & Johnson
NYSE:JNJ
|
419B USD |
31%
|
12%
|
18%
|
14%
|
|
| CH |
|
Roche Holding AG
SIX:ROG
|
198.6B CHF |
27%
|
9%
|
29%
|
20%
|
|
| UK |
|
AstraZeneca PLC
LSE:AZN
|
178.6B GBP |
20%
|
8%
|
18%
|
14%
|
|
| CH |
|
Novartis AG
SIX:NOVN
|
190.2B CHF |
33%
|
14%
|
26%
|
18%
|
|
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.4T DKK |
79%
|
26%
|
63%
|
32%
|
|
| US |
|
Merck & Co Inc
NYSE:MRK
|
209.3B USD |
36%
|
14%
|
27%
|
20%
|
|
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
183.4B USD |
70%
|
-51%
|
5%
|
6%
|
|
| US |
|
Pfizer Inc
NYSE:PFE
|
141.9B USD |
12%
|
5%
|
10%
|
10%
|
Free Cash Flow
Free cash flow (FCF) is the money a company has left over after paying its operating expenses and capital expenditures. The more free cash flow a company has, the more it can allocate to dividends, paying down debt, and growth opportunities.
If a company has a decreasing free cash flow, that is not necessarily bad if the company is investing in its growth.
You don't have any saved screeners yet
